This further is supported by in vitro work in osteosarcoma U2-OS cells, where loss of STAG2 is associated with decreased activation of the PI3K pathway, evidenced by decreased phosphorylation of PI3K, Akt, and mTOR [36]. Here, STAG2 is linked to osteosarcoma.